In vitro and in vivo efficacies of T-3811ME (BMS-284756) against Mycoplasma pneumoniae

被引：28

作者：

Takahata, M ^{[1
]}

Shimakura, M ^{[1
]}

Hori, R ^{[1
]}

Kizawa, K ^{[1
]}

Todo, Y ^{[1
]}

Minami, S ^{[1
]}

Watanabe, Y ^{[1
]}

Narita, H ^{[1
]}

机构：

[1] Toyama Chem Co Ltd, Res Labs, Toyama, Japan

来源：

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY | 2001年 / 45卷 / 01期

关键词：

D O I：

10.1128/AAC.45.1.312-315.2001

中图分类号：

Q93 [微生物学];

学科分类号：

071005 ; 100705 ;

摘要：

T-3811, the free base of T-3811ME (BMS-284756), a new des-F(6)-quinolone, showed a potent in vitro activity (MIC at which 90% of the isolates tested are inhibited [MIC90], 0.0313 mug/ml) against Mycoplasma pneumoniae. The MIC90 of T-3811 was 4-fold higher than that of clarithromycin but was 4- to 8 fold lower than those of trovafloxacin, gatifloxacin, gemifloxacin, and moxifloxacin and was 16- to 32-fold lower than those of levofloxacin, ciprofloxacin, and minocycline. In an experimental M. pneumoniae pneumonia model in hamsters, after the administration of T-3811ME (20 mg/kg of body weight as T-3811, once daily orally) for 5 days, the reduction of viable cells of M. pneumoniae in bronchoalveolar lavage fluid was greater than those of trovafloxacin, levofloxacin, and clarithromycin (20 and 40 mg/kg, orally) (P < 0.05).

引用

页码：312 / 315

页数：4

共 26 条

[21] TRANSITION MUTATIONS IN THE 23S RIBOSOMAL-RNA OF ERYTHROMYCIN-RESISTANT ISOLATES OF MYCOPLASMA-PNEUMONIAE [J].